stockrow
Saturday 7 November 2026
Export VSTM’s income statement to Excel — free account
Verastem, Inc.
VSTM Healthcare Biotechnology
Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024.
- Revenue
- +113.6%
- EPS
- +45.2%
- Free cash flow
- +24.5%
- Total debt
- +52.9%
Quarter to September 2026, against a year earlier
8.43
0.95
−10.13%
Follow VSTM
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.13 | 4.37 | 10.51 | 13.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.26) | (8.71) | (10.00) | (17.86) | |
P/B ratio |
80.68 | 7.65 | 6.37 | 9.35 | |
Price to Tangible BV |
0.00 | 11.21 | 7.94 | 13.12 | |
EV/Sales |
7.59 | 3.77 | 8.52 | 10.17 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.77) | (2.03) | (2.80) | (3.03) | |
EV/FCF |
(4.77) | (2.03) | (2.80) | (3.03) | |
Quick Ratio |
1.67 | 2.12 | 2.87 | 2.96 | |
Current Ratio |
1.93 | 2.25 | 3.04 | 3.09 | |
Net Debt/EBITDA |
0.00 | 1.92 | 2.43 | 3.12 | |
Debt/Assets |
52.01% | 35.72% | 32.10% | 30.97% | |
Debt/Equity |
11.82 | 1.48 | 0.89 | 1.33 | |
Asset Turnover |
0.49 | 0.43 | 0.28 | 0.24 | |
Operating CF/Net income |
0.45 | 1.27 | 1.42 | 0.91 | |
Capex/Depreciation |
— | 0.00 | 0.00 | (4.82) | |
Interest Coverage |
(354.83) | (90.86) | (117.53) | (99.94) | |
Research and Development Expense of Revenue |
286.55% | 103.14% | 204.69% | 180.62% | |
Selling, General and Administrative Expense of Revenue |
110.30% | 68.39% | 119.43% | 139.42% | |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
15.45% | 8.56% | 10.96% | 11.55% | |
Graham Net Nets |
(0.02) | 0.05 | 0.11 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(22.98%) | (64.40%) | (47.17%) | (40.03%) | |
Free Cash Flow Yield |
(19.58%) | (42.42%) | (28.98%) | (25.70%) | |
Revenue per Share |
0.24 | 0.40 | 0.19 | 0.25 | |
Operating CF per Share |
(0.33) | (0.44) | (0.53) | (0.43) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.33) | (0.44) | (0.53) | (0.45) | |
Cash per Share |
1.71 | 1.36 | 1.85 | 2.96 | |
Shareholders Equity per Share |
0.10 | 0.50 | 0.83 | 0.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.10 | 0.50 | 0.83 | 0.83 | |
Free Cash Flow |
(33.59) | (43.91) | (52.12) | (31.30) | |
Working Capital |
96.05 | 98.03 | 136.06 | 151.15 | |
Capital Expenditures |
— | — | — | (1.34) | |
Net Current Asset Value |
(20.16) | 19.63 | 56.87 | 34.17 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 15.68 | 5.28 | 4.61 | |
Average Payables |
15.06 | 13.02 | 8.40 | 8.24 | |
Average Inventory |
2.02 | 1.78 | 4.30 | 4.07 | |
Average Assets |
203.24 | 201.39 | 179.75 | 173.99 | |
Average Common Equity |
(2.71) | 43.02 | 24.67 | 14.15 |
Columns are period end dates · fundamentals updated 5 Nov 2026